GI Innovation said on Thursday that it has received orphan drug designation (ODD) from the U.S. FDA for its Merkel cell cancer (MCC) drug, GI-101.MCC is a rare skin cancer which appears as a flesh-colored or bluish-red nodule, on the face, head or neck with a tendency to spread quickly to other part
Pfizer's Ibrance (palbociclib), the first CDK4/6 inhibitor that rewrote the history of treating metastatic hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, seems to have failed to enter the early treatment market.Professor Angela DeMichele of the
About half of the patients suffering from hair loss in Korea are women.According to data by the National Health Insurance Service (NHIS) submitted to Rep. Kim Won-i of the Democratic Party of Korea, the number of people who received treatment for pathologic hair loss in 2021 was 244,609, of which 10
Jeil Pharmaceutical said on Wednesday that it has released its four-drug combination therapy TelmicanQ for treating high blood pressure and dyslipidemia.TelmicanQ contains four ingredients --telmisartan, rosuvastatin calcium, ezetimibe, and amlodipine besylate-- in one pill to treat hypertension and
Merck Biopharma Korea has become the second company in Korea to launch a treatment for non-small cell lung cancer (NSCLC) with METex14 skipping alterations with Tepmetko (ingredient: tepotinib).The Ministry of Food and Drug Safety approved two anticancer drugs targeting MET mutations -- Tepmetko and
LG Chem said on Tuesday that it would acquire Aveo Oncology for $566 million (about 800 billion won) which marks the first time a Korean company has acquired a foreign drugmaker with a new FDA-approved drug.Aveo was established in Boston in 2002 and has secured comprehensive capabilities specialized
Novo Nordisk Korea said Tuesday it has appointed Sasha Semienchuk, senior director of marketing at Novo Nordisk Japan, as its new general manager (GM).Semienchuk has more than 20 years of experience in various fields such as sales, marketing, research, and management at multinational pharmaceutical
Dong-A ST steps up commercializing two- or three-drug therapy by combining DPP-4 inhibitor diabetes treatment Suganon and SLGT-2 inhibitors.According to KIPRIS, a patent-related information search service, on Tuesday, Dong-A ST applied for patents for two trademarks – Sugadapa and Sugadapamet – on J
Affiliates or subsidiaries of Korean pharmaceutical companies have been announcing their plans to conduct an initial public offering (IPO) to secure funds for clinical research and develop new drugs.Most recently, Idience, Ildong Pharmaceutical Group's new drug development company, said on Monday th
According to the latest report by UNAIDS, a U.N. agency exclusively responsible for AIDS, the number of new HIV infections worldwide totaled about 1.5 million in 2021, more than a million more than the global target.UNAIDS, which declared to terminate AIDS by 2030, puts its foremost priority on HIV
Inventage Lab, a company specializing in gene therapy, said that it signed a joint development and commercialization contract with Chong Kun Dang Pharmaceutical for a long-lasting persistent dementia injection, IVL3003, on Monday.The pipeline, which gave Chong Kun Dang exclusive rights, is a dementi
M2N Bio, an investment partner in Pacylex Pharmaceuticals, said that the PCLX-001 drug to treat patients with acute myeloid leukemia (AML) received U.S. FDA orphan drug designation (ODD) on Saturday.PCLX-001 is the first N-myristoyltransferase (NMT) inhibitor in its class undergoing phase 1 clinical
Both Moderna and Pfizer’s Covid-19 bivalent vaccines have landed in Korea as a booster shot against the Omicron variants.Moderna is expanding the mRNA scope beyond Covid-19 vaccines to tackle other global health issues, said Moderna’s Senior Director of Bacteriology and Infectious Disease Research,
Yuhan Corp. has set about to secure indications for its non-small cell lung cancer (NSCLC) drug, Leclaza (lazertinib), as the first-line treatment.In a public notice on Friday, Yuhan unveiled part of the topline results of phase 3 clinical trial of Leclazae to win approval as the first-line treatmen
The market capitalization of Icure Pharmaceutical has shrunk close to 90 billion won ($56 million), which could disrupt its plan to increase 80 billion won in capital.As of 2:40 p.m, Friday, the company’s shares stood at 4,850 won, up 7.3 percent from the previous trading day, with a market cap of 9
Daewoong Pharmaceutical has released the results of a study on the indication of its P-CAB (potassium-competitive acid blockers)-based drug, Fexuclue (fexuprazan hydrochloride), to treat gastritis at the United European Gastroenterology Week (UEGW) 2022.Daewoong said it unveiled the phase 3 clinical
Dong-A ST said Wednesday it released the results of the phase 3 clinical trial of Evogliptin plus three-drug combination therapy at the European Association for the Study of Diabetes (EASD) conference in Stockholm from Sept. 19-23.Professor Yoon Keon-ho of the Department of Endocrine Metabolism at S
Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan), the two breast cancer therapies based on the next-generation antibody-drug conjugates (ADC), will likely take the lead in the cancer’s innovative treatment across the board.The first-generation ADC developed by Roche, Kadcyla (tr
ViGenCell, an immune cell therapy developer, said the Ministry of Food and Drug Safety has granted compassionate use approval for VT-Tri, an acute myeloid leukemia (AML) treatment.Compassionate use permits the use of investigational drugs for treating patients with severe and life-threatening illnes
The Korea Exchange (KRX) held a corporate review committee on Thursday and decided to maintain the listing of SillaJen on the tech-heavy Kosdaq market.With the decision, SillaJen's shares will resume trading on Thursday.The company used to be one of the most prominent local biopharmaceutical compani